drugset

drugset / Trial / NCT01181622

A Safety and Tolerability Study of Denufosol in 2-4 Year Olds

NCT01181622 ↗

Phase 2 Completed 25 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of denufosol 60 mg TID in pediatric CF patients 2 to 4 years of age

Timeline

Start: 2010-08
Primary completion: 2010-10
Completion: 2010-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	denufosol	Other / unclassified	60 mg	Inhaled

Indications